# Pharmacovigilance signal detection of psychiatric adverse events induced by third-generation antiepileptic drugs in children

**Authors:** Wenfang Sun, Yali Li, Binbin Xia, Liushui Li, Jing Chen, Yang Liu, Jingyao Pang, Fang Liu, Hua Cheng

PMC · DOI: 10.3389/fphar.2025.1711879 · Frontiers in Pharmacology · 2026-01-05

## TL;DR

This study identifies psychiatric side effects in children taking third-generation epilepsy drugs, highlighting perampanel as particularly risky.

## Contribution

The study provides new pharmacovigilance signals for psychiatric adverse events in children using third-generation antiepileptic drugs.

## Key findings

- Perampanel showed significant psychiatric risks like aggression and suicidal ideation.
- Lacosamide and eslicarbazepine had lower psychiatric adverse event signals.
- Brivaracetam showed moderate psychiatric risk compared to other drugs.

## Abstract

The present study was a retrospective pharmacovigilance analysis to identify pharmacovigilance signals of psychiatric adverse events (AEs) associated with the clinical use of third-generation antiepileptic drugs (AEDs) in children, thereby providing a reference for clinical drug selection and pharmaceutical care.

The data were obtained from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Reports involving patients under 18 years old were retrieved using the generic and brand names of four drugs: lacosamide, perampanel, brivaracetam, and eslicarbazepine. Positive safety signals were detected using the Reporting Odds Ratio (ROR) method and the Bayesian Confidence Propagation Neural Network (BCPNN) method for further analysis. The number of AEs ≥3 cases, ROR value 95% confidence interval lower limit >1 and information component 25 (IC025) must be above 0 was considered statistically significant.

Lacosamide and eslicarbazepine acetate demonstrated relatively lower signals of psychiatric AEs, while brivaracetam was associated with a certain degree of psychiatric risk. In contrast, perampanel requires heightened clinical vigilance due to its potential to induce severe psychiatric and behavioral abnormalities, particularly aggression, suicidal ideation, and homicidal ideation. The most significant psychiatric safety signals for perampanel, based on ROR, were homicidal ideation (ROR = 23.51 [9.72, 56.89]), aggression (ROR = 17.81 [13.85, 22.92]), and psychotic disorders (ROR = 16.94 [9.57, 29.99]).

The findings of this study provide a reference for clinical selection of third-generation AEDs. When initiating treatment in children, clinicians should consider the differential psychiatric risk profiles of these third-generation AEDs, monitor potential psychiatric side effects and adjust prescriptions promptly.

## Linked entities

- **Chemicals:** lacosamide (PubChem CID 219078), perampanel (PubChem CID 9924495), brivaracetam (PubChem CID 9837243), eslicarbazepine (PubChem CID 9881504)
- **Diseases:** epilepsy (MONDO:0005027)

## Full-text entities

- **Diseases:** psychiatric AEs (MESH:D064420), behavioral abnormalities (MESH:D001523), aggression (MESH:D010554), homicidal ideation (MESH:D001072), psychotic disorders (MESH:D011618)
- **Chemicals:** eslicarbazepine (MESH:C571001), perampanel (MESH:C551441), Lacosamide (MESH:D000078334), brivaracetam (MESH:C482793), eslicarbazepine acetate (MESH:C416835)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12812890/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12812890/full.md

---
Source: https://tomesphere.com/paper/PMC12812890